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concomitant antipsychotic therapy, 60 day overlap); concomi-
tant psychotropics (30 day overlap, no polypharmacy),
polypharmacy + psychotropics; or monotherapy (no polyphar-
macy or psychotropics). ICD-9 codes (290.xx-319.xx) were used
to identify mental health diagnoses and related hospitalizations.
Total health care and drug costs were calculated for 365 days
after the index antipsychotic claim. Groups were compared using
chi-square and ANOVA tests. RESULTS: A total of 53.1%
receiving antipsychotics began and stayed on monotherapy;
39.8% received concomitant psychotropics only; 3.2%
polypharmacy only; and 3.9% polypharmacy + psychotropics.
Polypharmacy rates varied by year (p < 0.001), declining
between 1998 and 2000, then increasing through 2002. Patients
receiving polypharmacy were more likely to be male (p < 0.001),
have diagnosed schizophrenia (p < 0.001) and a mental health-
related hospitalization (p < 0.001). Median total healthcare costs
varied by therapy regimen (Mono, $3156; Psycho, $5131; Poly,
$6396; Poly + Psycho, $9342; p < 0.001). Median total drug
costs varied by therapy regimen (Mono, $1575, Psycho, $3169;
Poly, $3838; Poly + Psycho, $5833; p < 0.001). The weighted
contribution of total health care costs by regimen was: Mono,
49%; Psycho, 41%; Poly, 4%; Poly + Psycho, 6%. CONCLU-
SION: Polypharmacy rates were low during the study period,
were higher in patients with more severe mental illness, and rep-
resented a small yet signiﬁcant component of health care costs.
Future research will investigate predictors of polypharmacy and
health care costs.
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OBJECTIVE: To assess healthcare utilization and associated cost
in schizophrenia and schizoaffective patients pre/post risperidone
long-acting injectable (RLAI) treatment initiation. METHODS:
A retrospective evaluation utilized pharmacy and medical claims
to assess healthcare resource utilization and costs of adult schiz-
ophrenia patients from a mental health subset of managed care
data. Inclusion criteria required a diagnosis of schizophrenia or
schizoaffective disorder, at least one claim for RLAI between
December 2003 and June 2004, and six months of continuous
eligibility criteria pre and post the initial RLAI claim. The initial
RLAI claim served as the index date. The observation period was
12 months, including 6-month pre and 6-month post RLAI treat-
ment initiation where patients served as their own control.
Healthcare utilization outcome variables included hospitaliza-
tions, emergency room use, outpatient visits, and medications.
Costs represent the amount paid by the health plan for services.
RESULTS: Results are available for the 26 patients meeting
inclusion criteria. Mean patient age was 37 ± 13.4 years, and
53.8% of the population were male. The mean number hospi-
talizations per patient decreased from 0.77 in the pre-period to
0.35 in the post-period (p = 0.06). The costs for hospitalizations
decreased from $14,456 ± $28,745 in the pre-period to $4,201
± $13,876 (p < 0.05). Outpatient utilization remained statisti-
cally unchanged between the pre and post period, while the costs
for psychoactive medications signiﬁcantly increased in the post
period. Total healthcare costs trended downward, from an
average of $22,650 ± $30,856 in the pre-period to $15,182 ±
$18,209 in the post-period (p = 0.09). Sensitivity analyses con-
ducted around the index date resulted in a statistically signiﬁcant
decrease in total health care costs in the post period. CON-
CLUSIONS: In this US managed care patient population, hospi-
talization costs signiﬁcantly decreased post (RLAI) treatment
initiation. Further studies with larger sample sizes are needed to
conﬁrm ﬁndings.
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OBJECTIVES: Evaluate the effects of open access to atypical
antipsychotics on patients with schizophrenia recently dis-
charged from a hospital. METHODS: Retrospective database
analysis of episodes of antipsychotic drug therapy using data
from the California Medicaid (Medi-Cal) program. Episodes ini-
tiated between January 1994 and August 2000 were included in
this analysis. Open access was implemented in October 1997.
Selection criteria include a schizophrenia diagnosis; 6 months of
data prior to and 12 months of data post episode start and insti-
tutionalization in an acute or psychiatric hospital within the
prior 30 days. The ﬁnal data set consisted of 3290 post-
discharge episodes of treatment. Multivariate logistic regression
models were estimated for the likelihood of using an atypical
antipsychotics post-discharge and the likelihood of re-
institutionalization in an acute or psychiatric hospital or nursing
home. RESULTS: Open access increased the use of atypical
antipsychotics by discharged patients by 8-fold (CI:
6.154–10.636). Moreover, use of atypical antipsychotics
increased disproportionately for blacks (OR 0.514 vs. 0.914)
and for other minorities (OR 0.933 vs. 1.194) relative to white
patients. While access to atypical antipsychotics improved for
black patients with open access, their use rates were still not
equal to white patients. However, the estimated changes in access
for other minority patients after implementation of open access
did achieve statistical signiﬁcance such that there was no statis-
tically signiﬁcant difference compared to whites in the open
access period. But, more importantly, open access decreased the
risk of re-institutionalization in an acute or psychiatric hospital
(OR 0.67, CI: 0.557–0.816) and long term care (LTC) facilities
(OR 0.67, CI: 0.493–0.916). CONCLUSIONS: Granting open
access to innovative drugs reduced racial disparities in the use of
atypical antipsychotics for minority patients upon hospital dis-
charge. Open access reduced the risk of re-institutionalization in
acute hospitals and long term care facilities.
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Health care policy makers need valid, objective, unbiased, and
methodologically sound technology assessments. Frequently the
approach established by the National Institute for Health and
Clinical Excellence (NICE) is regarded as a reference standard
internationally. OBJECTIVE: To use the recent appraisal of
attention-deﬁcit/hyperactivity disorder (ADHD) treatments as a
case study to explore whether NICE technology appraisals meet
quality expectations when addressing complex clinical problems.
METHOD: Tracking the ADHD treatment appraisal by NICE
